Summary

Rosetta Genomics, Ltd. (RGL) is a biotechnology company. The company discovers, develops and commercializes next generation diagnostic tests for personalized medicine. It provides testing services such as rosetta cancer origin test, resetta lung cancer test, rosetta kidney cancer test and rosetta mesothelioma test. RGL product pipeline includes tests such as thyroid neoplasia, oncology project, kidney rejection, Alzheimer's disease, therapeutics and CMV. The company has distribution network in Australia, New Zealand, Singapore, Canada, Greece, India, Saudi Arabia, Qatar, the UAE, Israel and Turkey. The company has its presence in the UA. RGL is headquartered in Rehovot, Israel.

Rosetta Genomics, Ltd. (ROSG) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Rosetta Genomics, Ltd., Medical Equipment, Deals By Year, 2008 to YTD 2014 7
Rosetta Genomics, Ltd., Medical Equipment Deals By Type, 2008 to YTD 2014 8
Rosetta Genomics, Ltd., Medical Equipment, Deals By Region, 2008 to YTD 2014 9
Rosetta Genomics, Ltd., Medical Equipment, Deals By Market, 2008 to YTD 2014 10
Rosetta Genomics, Ltd., Medical Equipment, Deals Summary, 2008 to YTD 2014 11
Rosetta Genomics, Ltd., Medical Equipment, Deal Details 14
Partnerships 14
Rosetta Genomics To Enter Into Licensing Agreement For microRNA Intellectual Property And Technology 14
Rosetta Enters Into Licensing Agreement For Patents Related To Cancer Applications 15
Rosetta Genomics Enters Into Licensing Agreement With Avatao Biotech 16
Rosetta Genomics Enters Into Licensing Agreement With Roche 17
Rosetta Genomics Enters into Co-Development Agreement with Global Pharma Company 18
Rosetta Genomics Enters into Co-Development Agreement with Moffitt Cancer Center 19
Rosetta Genomics Enters Into Co-Development Agreement With Rabin Medical 20
Rosetta Genomics Expands Distribution Agreement With Genekor 21
Rosetta Genomics Enters Into Agreement With Ramot To Develop Nano-Carrier Delivery System To Treat Cancer 22
Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics 23
Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 24
Rosetta Genomics Enters Into Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 25
Rosetta Genomics Enters Into Agreement With Tel Hashomer Medical Research, Infrastructure And Services 27
Rosetta Genomics Enters Into Agreement With Carmel Medical Center 28
Rosetta Genomics Enters Into Distribution Agreement With Genekor 29
Rosetta Genomics Enters Into An Agreement With Genetic Technologies 30
Rosetta Genomics Enters Into Distribution Agreement With Super Religare Labs 31
Warnex Signs Distribution Agreement With Rosetta Genomics 32
Teva Pharma Enters Into An Agreement With Rosetta Genomics 33
Rosetta Genomics Enters Into An Agreement With The University of Texas M. D. Anderson Cancer Center 34
Rosetta Genomics Enters Into Agreement With University Of California 35
Rosetta Genomics Enters Into Agreement With Henry Ford Health System 36
Prometheus Labs Signs An Agreement With Rosetta Genomics 37
Equity Offering 38
Rosetta Genomics Files Shelf Registration Statement For Public Offering Of Securities For Up To US$75 Million 38
Rosetta Genomics Completes Underwriters' Exercise Of Over-Allotment Option For US$4 Million 39
Rosetta Genomics Completes Private Placement Of Shares For US$6.6 Million 41
Rosetta Genomics Completes Private Placement Of Shares For US$2 Million 43
Rosetta Genomics Completes Private Placement Of Shares For US$1.4 Million 44
Rosetta Genomics Completes Private Placement Of Common Stock For US$1.5 Million 45
Rosetta Genomics Completes Private Placement For US$2.7 Million 47
Rosetta Genomics Completes Registered Direct Offering For US$3.3 Million 49
Rosetta Genomics Completes Private Placement For US$2.5 Million 51
Rosetta Genomics Completes Registered Direct Offering Of Shares For US$5.1 Million 53
Rosetta Genomics Completes Private Placement Of US$8 Million 55
Debt Offering 56
Rosetta Genomics Completes Private Placement Of Debentures Due 2013 For US$1.75 Million 56
Rosetta Genomics, Ltd. - Key Competitors 57
Key Employees 58
Locations And Subsidiaries 59
Head Office 59
Other Locations and Subsidiaries 59
Recent Developments 60
Strategy And Business Planning 60
Sep 02, 2014: Rosetta Genomics and Moffitt Cancer Center Enter Into Strategic Alliance to Develop microRNA-Based Cancer Diagnostics 60
Feb 18, 2014: Rosetta Genomics Executes Agreement With MultiPlan 60
Dec 12, 2013: Rosetta Collaborative Study Profiling microRNAs Published in Clinical and Translational Oncology 61
Sep 09, 2013: Rosetta Genomics Executes Credentialing Agreements With Two National Healthcare Preferred Provider Networks 61
Jun 04, 2013: Rosetta Genomics To Increase Number Of US Sales Territories 62
Financial Announcements 63
Sep 17, 2014: Rosetta Genomics Reports Financial Results for the First Half of 2014 63
Mar 31, 2014: Rosetta Genomics Reports 2013 Financial Results 64
Sep 10, 2013: Rosetta Genomics Reports Financial Results for the First Six Months of 2013 66
Corporate Communications 68
Aug 18, 2014: Rosetta Genomics Expands Management Team With Appointment of Douglas Sites as Executive Vice President of Sales and Marketing 68
Feb 18, 2014: Rosetta Genomics Appoints Kevin Watson as Director, Reimbursement-Managed Care 68
Legal and Regulatory 69
Apr 18, 2013: Rosetta Genomics Reaches Settlement Agreement With Sanra In Connection With Previous Sale Of Parkway 69
Government and Public Interest 69
Nov 27, 2013: Rosetta Genomics to Participate in the LD Micro Conference 69
Sep 25, 2013: Rosetta Genomics to Participate at the Aegis Capital 2013 Healthcare Conference 69
Sep 04, 2013: Rosetta Genomics to Host Business Update Conference Call on September 10, 2013 70
Product News 70
Jul 22, 2014: Rosetta Genomics Receives Final New York State Approval for Rosetta Kidney Cancer Test 70
Jul 10, 2014: Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Treatment of Ovarian Cancer 70
Jun 09, 2014: Rosetta Genomics and Moffitt Cancer Center Enter Into Agreement to Advance Development of microRNA-Based Cancer Diagnostic 71
Dec 09, 2013: Rosetta Genomics Announces New York State Approval for the Rosetta Kidney Cancer Test 72
Jul 25, 2013: Rosetta Genomics Receives Notice of Allowance for Key U.S. Patent for the Rosetta Lung Cancer Test 72
Jun 13, 2013: Novitas Solutions Issues Final Local Coverage Determination For Rosetta Cancer Origin Test 73
Jun 07, 2013: Rosetta Genomics Executes Credentialing Agreement With TRPN For Rosetta Cancer Origin Test 73
Jun 06, 2013: Rosetta Genomics Announces Acceptance For Publication Of Rosetta Cancer Origin Test Manuscript Data In Molecular Cancer 74
May 20, 2013: Rosetta Genomics Executes Credentialing Agreement With Prime Health Services For miRview mets2 74
Apr 01, 2013: Rosetta Genomics Announces Acceptance For Publication Of Kidney Cancer microRNA Diagnostic Manuscript By Molecular Oncology 75
Feb 07, 2013: Rosetta Genomics Reports Data Demonstrating Ability Of microRNAs To Predict Progression Of Bladder Cancer 75
Product Approvals 76
Jul 22, 2014: Rosetta Genomics Receives Final New York State Approval for Rosetta Kidney Cancer Test 76
Dec 09, 2013: Rosetta Genomics Announces New York State Approval for the Rosetta Kidney Cancer Test 77
Other Significant Developments 77
Nov 20, 2013: Rosetta Genomics Expands microRNA Cancer Testing Services Agreement With GeneKor to Include Turkey and Romania 77
Aug 05, 2013: Rosetta Genomics Announces Launch of New Website 78
May 10, 2013: Rosetta Genomics Gets Full Settlement Payment From Sanra Laboratories 78
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79

List of Tables
Rosetta Genomics, Ltd., Medical Equipment, Key Facts, 2013 1
Rosetta Genomics, Ltd., Medical Equipment, Deals Summary, 2008 to YTD 2014 1
Rosetta Genomics, Ltd., Medical Equipment, Deals By Year, 2008 to YTD 2014 8
Rosetta Genomics, Ltd., Medical Equipment Deals By Type, 2008 to YTD 2014 9
Rosetta Genomics, Ltd., Medical Equipment, Deals By Region, 2008 to YTD 2014 10
Rosetta Genomics, Ltd., Deals By Market, 2008 to YTD 2014 11
Rosetta Genomics, Ltd., Medical Equipment, Deals Summary, 2008 to YTD 2014 12
Rosetta Genomics To Enter Into Licensing Agreement For microRNA Intellectual Property And Technology 15
Rosetta Enters Into Licensing Agreement For Patents Related To Cancer Applications 16
Rosetta Genomics Enters Into Licensing Agreement With Avatao Biotech 17
Rosetta Genomics Enters Into Licensing Agreement With Roche 18
Rosetta Genomics Enters into Co-Development Agreement with Global Pharma Company 19
Rosetta Genomics Enters into Co-Development Agreement with Moffitt Cancer Center 20
Rosetta Genomics Enters Into Co-Development Agreement With Rabin Medical 21
Rosetta Genomics Expands Distribution Agreement With Genekor 22
Rosetta Genomics Enters Into Agreement With Ramot To Develop Nano-Carrier Delivery System To Treat Cancer 23
Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics 24
Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 25
Rosetta Genomics Enters Into Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 26
Rosetta Genomics Enters Into Agreement With Tel Hashomer Medical Research, Infrastructure And Services 28
Rosetta Genomics Enters Into Agreement With Carmel Medical Center 29
Rosetta Genomics Enters Into Distribution Agreement With Genekor 30
Rosetta Genomics Enters Into An Agreement With Genetic Technologies 31
Rosetta Genomics Enters Into Distribution Agreement With Super Religare Labs 32
Warnex Signs Distribution Agreement With Rosetta Genomics 33
Teva Pharma Enters Into An Agreement With Rosetta Genomics 34
Rosetta Genomics Enters Into An Agreement With The University of Texas M. D. Anderson Cancer Center 35
Rosetta Genomics Enters Into Agreement With University Of California 36
Rosetta Genomics Enters Into Agreement With Henry Ford Health System 37
Prometheus Labs Signs An Agreement With Rosetta Genomics 38
Rosetta Genomics Files Shelf Registration Statement For Public Offering Of Securities For Up To US$75 Million 39
Rosetta Genomics Completes Underwriters' Exercise Of Over-Allotment Option For US$4 Million 40
Rosetta Genomics Completes Private Placement Of Shares For US$6.6 Million 42
Rosetta Genomics Completes Private Placement Of Shares For US$2 Million 44
Rosetta Genomics Completes Private Placement Of Shares For US$1.4 Million 45
Rosetta Genomics Completes Private Placement Of Common Stock For US$1.5 Million 46
Rosetta Genomics Completes Private Placement For US$2.7 Million 48
Rosetta Genomics Completes Registered Direct Offering For US$3.3 Million 50
Rosetta Genomics Completes Private Placement For US$2.5 Million 52
Rosetta Genomics Completes Registered Direct Offering Of Shares For US$5.1 Million 54
Rosetta Genomics Completes Private Placement Of US$8 Million 56
Rosetta Genomics Completes Private Placement Of Debentures Due 2013 For US$1.75 Million 57
Rosetta Genomics, Ltd., Key Competitors 58
Rosetta Genomics, Ltd., Key Employees 59
Rosetta Genomics, Ltd., Other Locations 60
Rosetta Genomics, Ltd., Subsidiaries 60

List of Figures
Rosetta Genomics, Ltd., Medical Equipment, Deals by Type, 2008 to YTD 2014 1
Rosetta Genomics, Ltd., Medical Equipment, Deals By Year, 2008 to YTD 2014 1
Rosetta Genomics, Ltd., Medical Equipment, Deals By Region, 2008 to YTD 2014 1
Rosetta Genomics, Ltd., Medical Equipment, Deals By Market, 2008 to YTD 2014 1
Rosetta Genomics, Ltd., Medical Equipment, Deals By Year, 2008 to YTD 2014 8
Rosetta Genomics, Ltd., Medical Equipment, Deals by Type, 2008 to YTD 2014 9
Rosetta Genomics, Ltd., Medical Equipment, Deals By Region, 2008 to YTD 2014 10
Rosetta Genomics, Ltd., Medical Equipment, Deals by Market, 2008 to YTD 2014 11

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

AmpliPhi Biosciences Corporation (formerly Targeted Genetics Corporation) - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

AmpliPhi Biosciences Corporation (formerly Targeted Genetics Corporation) - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • Company report
  • September 2014
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...

Rosetta Genomics, Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Rosetta Genomics, Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • Company report
  • September 2014
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...

Myriad Genetics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Myriad Genetics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • Company report
  • September 2014
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.